TAKE Limited Reports Strong Q1 FY27: Revenue ₹30.37 Cr, Net Profit ₹1.06 Cr, Enters Longevity Market
TAKE Limited reported strong Q1 FY27 results with consolidated revenue of ₹30.37 Cr and a net profit of ₹1.06 Cr, reversing a prior year loss. Finance costs dropped 99.6% to ₹0.07 Lakhs. The company also announced its strategic entry into the Longevity, Biohacking, and Preventive Healthcare market.
The announcement details a significant financial turnaround and a strategic pivot into a new, high-growth market, which is likely to have a substantial impact on the company's future performance and valuation.
The company reported a significant turnaround in its financial performance, with strong revenue growth and a return to profitability. The strategic entry into a new high-growth market also contributes to a positive outlook.
TAKE Limited announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27), reporting a significant turnaround. The company achieved consolidated revenue from operations of ₹3,037.33 Lakhs (₹30.37 Crore), a substantial increase from nil revenue in the prior year's comparable quarter. Total income reached ₹3,170.11 Lakhs (₹31.70 Crore).
The company has returned to profitability, posting a consolidated net profit after tax (PAT) of ₹106.26 Lakhs (₹1.06 Crore), a marked improvement from a net loss of ₹(91.00) Lakhs in Q1 FY26. Finance costs saw a dramatic reduction of 99.62% year-on-year, dropping to ₹0.07 Lakhs from ₹17.50 Lakhs in Q1 FY26, attributed to debt elimination and a cleaner capital structure. Basic and diluted earnings per share (EPS) turned positive at ₹0.07 per share.
On a standalone basis, revenue from operations surged to ₹1,196.90 Lakhs from ₹0.65 Lakhs in Q1 FY26, with net profit turning positive at ₹96.83 Lakhs, compared to a net loss of ₹(216.45) Lakhs in the same period last year.
In addition to its financial performance, TAKE Limited announced its strategic entry into the Longevity, Biohacking, and Preventive Healthcare market. This move leverages the company's expertise in life sciences, clinical research, and regulatory execution. The strategy involves integrating science-backed nutraceuticals and biohacking consumer products with technology-enabled predictive digital tools to optimize metabolic health, sleep, cognition, and biological aging. The company aims to build a scalable, high-margin platform addressing the growing demand for proactive health optimization.
Parmeshvar Dhangare, Director of TAKE Limited, commented, "Our Q1 FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finance costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness."
What to do with a filing like this
Take Solutions Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Take Solutions Limited. Read the original for the full detail.